Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedDec 14, 2025
DataAggregated Company Financials
Companies542
  • 7D-0.9%
  • 3M21.1%
  • 1Y20.5%
  • YTDn/a

Over the last 7 days, the Biotech industry has dropped 1.0%, driven by Alnylam Pharmaceuticals declining 13%. On the other hand Kymera Therapeutics is actually up 35%. Over the past 12 months, the industry was up 20%. Earnings are forecast to grow by 24% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 14 Dec 2025US$1.2tUS$163.7b-US$15,628,369,300.4319x-78x7.4x
Tue, 11 Nov 2025US$1.1tUS$163.6b-US$15,778,894,049.8917.1x-71.9x6.9x
Thu, 09 Oct 2025US$1.1tUS$163.4b-US$18,204,173,729.7516.7x-62.5x7x
Sat, 06 Sep 2025US$1.1tUS$163.6b-US$18,346,651,759.6015.7x-58.4x6.5x
Mon, 04 Aug 2025US$1.0tUS$158.4b-US$20,947,422,497.0215.8x-48.4x6.4x
Wed, 02 Jul 2025US$927.2bUS$156.0b-US$23,839,320,142.0917.5x-38.9x5.9x
Fri, 30 May 2025US$914.8bUS$155.9b-US$23,981,521,247.8015.7x-38.1x5.9x
Sun, 27 Apr 2025US$783.3bUS$119.2b-US$31,074,126,492.8219.8x-25.2x6.6x
Tue, 25 Mar 2025US$827.0bUS$118.6b-US$36,869,226,191.9320.7x-22.4x7x
Thu, 20 Feb 2025US$842.4bUS$116.6b-US$36,830,915,932.5217.4x-22.9x7.2x
Sat, 18 Jan 2025US$943.3bUS$149.4b-US$26,286,132,923.6717.3x-35.9x6.3x
Mon, 16 Dec 2024US$991.8bUS$150.0b-US$26,493,336,471.9416.6x-37.4x6.6x
Wed, 13 Nov 2024US$1.1tUS$149.6b-US$27,274,668,753.1816.1x-40.4x7.4x
Fri, 11 Oct 2024US$885.7bUS$113.1b-US$35,992,841,232.3420.3x-24.6x7.8x
Sun, 08 Sep 2024US$873.8bUS$113.1b-US$35,668,533,175.3222.2x-24.5x7.7x
Tue, 06 Aug 2024US$1.2tUS$165.8b-US$32,345,907,600.2024.9x-37x7.2x
Thu, 04 Jul 2024US$1.1tUS$164.5b-US$27,946,912,225.8427.9x-40.1x6.8x
Sat, 01 Jun 2024US$1.1tUS$164.6b-US$26,677,227,566.3227.4x-41.6x6.7x
Mon, 29 Apr 2024US$1.1tUS$164.6b-US$27,372,800,636.0922.6x-39.1x6.5x
Wed, 27 Mar 2024US$1.2tUS$164.4b-US$23,792,606,116.0221.2x-48.8x7.1x
Fri, 23 Feb 2024US$1.2tUS$169.0b-US$20,212,652,991.5813.2x-57x6.8x
Sun, 21 Jan 2024US$1.4tUS$204.8b-US$22,506,538,466.0018.5x-63.3x7x
Tue, 19 Dec 2023US$1.4tUS$204.7b-US$22,117,247,361.0019.2x-61x6.6x
Thu, 16 Nov 2023US$1.2tUS$204.7b-US$22,143,559,902.0018.4x-55.1x6x
Sat, 14 Oct 2023US$1.3tUS$207.3b-US$13,141,713,262.0016.6x-96.4x6.1x
Mon, 11 Sep 2023US$1.3tUS$207.5b-US$12,633,744,533.0017.4x-101x6.1x
Wed, 09 Aug 2023US$1.3tUS$206.4b-US$12,500,248,802.0016.4x-101x6.1x
Fri, 07 Jul 2023US$1.1tUS$186.2b-US$16,056,868,924.0013.2x-69.5x6x
Sun, 04 Jun 2023US$1.1tUS$185.9b-US$16,014,255,509.0011.4x-71.1x6.1x
Tue, 02 May 2023US$1.2tUS$197.0b-US$6,677,740,450.0014x-175.7x6x
Thu, 30 Mar 2023US$1.1tUS$198.3b-US$4,280,712,821.0013.8x-266.8x5.8x
Sat, 25 Feb 2023US$1.1tUS$200.5b-US$3,797,679,065.0014.2x-295.4x5.6x
Mon, 23 Jan 2023US$1.2tUS$203.8bUS$1.8b14.4x655.9x5.7x
Wed, 21 Dec 2022US$1.2tUS$203.3bUS$1.6b14.6x704x5.7x
Price to Earnings Ratio

704x


Total Market Cap: US$1.2tTotal Earnings: US$1.6bTotal Revenue: US$203.3bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -7.2x202320242025
Current Industry PE
  • Investors are optimistic on the American Biotechnology industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.6x is lower than the industry's current PS ratio of 7.5x.
Past Earnings Growth
  • Total earnings for the Biotechnology industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.0% per year, which is driving profits down.

Industry Comparison

How does U.S. Biotech compare with similar industries?

US Market-0.59%
Healthcare0.43%
Biotech-0.95%
Biotech-0.95%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
KYMR Kymera TherapeuticsUS$89.6834.6%
+US$2.4b		112.9%PS164x
REGN Regeneron PharmaceuticalsUS$741.293.2%
+US$2.4b		1.4%PE16.6x
ARWR Arrowhead PharmaceuticalsUS$70.0914.1%
+US$1.2b		220.8%PS11.5x
ASND Ascendis PharmaUS$220.427.3%
+US$915.3m		69.7%PS17.7x
ROIV Roivant SciencesUS$22.105.4%
+US$785.9m		86.7%PS756.1x

Latest News

AMGN
US$317.74
Amgen
7D
-3.7%
1Y
17.4%
NTRA
US$231.95
Natera
7D
-5.2%
1Y
39.3%
KYMR
US$89.68
Kymera Therapeutics
7D
34.6%
1Y
112.9%
REGN
US$741.29
Regeneron Pharmaceuticals
7D
3.2%
1Y
1.4%
MRNA
US$29.46
Moderna
7D
6.4%
1Y
-29.6%
INCY
US$95.41
Incyte
7D
-6.9%
1Y
39.2%
ALNY
US$397.55
Alnylam Pharmaceuticals
7D
-13.2%
1Y
62.0%

ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition

Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.
INSM
US$197.01
Insmed
7D
-3.4%
1Y
175.0%
ARWR
US$70.09
Arrowhead Pharmaceuticals
7D
14.1%
1Y
220.8%
IMVT
US$26.42
Immunovant
7D
15.7%
1Y
0.5%
ROIV
US$22.10
Roivant Sciences
7D
5.4%
1Y
86.7%
LEGN
US$22.32
Legend Biotech
7D
-20.7%
1Y
-36.4%

LEGN: Late Stage Pipeline Execution Will Drive Future Market Expansion

Analysts trimmed their price target on Legend Biotech by $4, to $90 from $94. This reflects slightly higher discount rate assumptions and marginally softer long term revenue growth expectations, while profit margin and valuation forecasts remain stable.
BIIB
US$174.10
Biogen
7D
-4.0%
1Y
16.0%

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.
VERA
US$49.80
Vera Therapeutics
7D
10.9%
1Y
13.1%
ABBV
US$223.32
AbbVie
7D
-1.2%
1Y
28.8%

ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution

Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.
ASND
US$220.42
Ascendis Pharma
7D
7.3%
1Y
69.7%

Ascendis: Q3 Results Validate The TransCon Platform

Dec 05